Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Mar;84(6):760–767. doi: 10.1054/bjoc.2000.1681

Codon 89 polymorphism in the human 5 α -reductase gene in primary breast cancer

A Scorilas 1,2, B Bharaj 1, M Giai 3, E P Diamandis 1
PMCID: PMC2363825  PMID: 11259089

Abstract

The enzyme human steroid 5-α reductase type II (SRD5A2) and androgen receptor (AR) are critical mediators of androgen action, suggesting a potential role in hormonally related cancers. The SRD5A2 gene harbours two frequent polymorphic sites, one in the coding region, at codon 89 of exon 1, where valine is substituted by leucine (V89L) and the other in the 3′ untranslated region (3′ UTR) where a variable number of dinucleotide TA repeat lengths exists. The V89L polymorphism is known to alter the activity of this enzyme. In the present study we examined 144 sporadic breast tumours from Italian patients for the V89L and TA polymorphisms by sequence and fragment analysis, respectively. Tumour extract prostate specific antigen (PSA) concentration as well as a number of well-established clinical and pathological parameters were evaluated. The results show that 53% of the tumours were homozygous for VV alleles, 37% were heterozygous for VL alleles and 10% were homozygous for LL alleles. TA(0) repeats were found in tumours with VV, LL and VL genotypes. TA(9) repeats were only found in VV homozygotes and were totally absent from either LL homozygotes or VL heterozygotes. PSA expression was significantly elevated in tumours with VV genotype. The presence of LL alleles in breast tumours is associated with earlier onset and shorter disease-free (RR = 2.65;P = 0.013) and overall survival (RR = 3.06;P = 0.014) rates. The VV genotype is associated with a more favourable prognosis. Our study suggests that the polymorphism in codon 89 of exon 1 of the human 5α-reductase gene is related with TA repeat genotypes, PSA expression and breast cancer prognosis. More specifically, we found that the LL genotype is also associated with earlier onset and more aggressive forms of breast cancer. Long-term-outcome studies are needed to investigate the relevance of this polymorphism to breast cancer susceptibility. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: point mutations; polymorphisms; 5α-reductase; androgens and breast cancer; breast cancer prognosis; hormones and cancer, SRD5A2, breast cancer, PSA, androgens

Full Text

The Full Text of this article is available as a PDF (212.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akalu A., Dlmajian D. A., Highshaw R. A., Nichols P. W., Reichardt J. K. Somatic mutations at the SRD5A2 locus encoding prostatic steroid 5alpha-reductase during prostate cancer progression. J Urol. 1999 Apr;161(4):1355–1358. [PubMed] [Google Scholar]
  2. Alexieva-Figusch J., Van Putten W. L., Blankenstein M. A., Blonk-Van Der Wijst J., Klijn J. G. The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer. Cancer. 1988 Feb 15;61(4):758–768. doi: 10.1002/1097-0142(19880215)61:4<758::aid-cncr2820610421>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  3. Ardavanis A., Gerakini F., Amanatidou A., Scorilas A., Pateras C., Garoufali A., Pissakas G., Stravolemos K., Apostolikas N., Yiotis I. Relationships between cathepsin-D, pS2 protein and hormonal receptors in breast cancer cytosols: inconsistency with their established prognostic significance. Anticancer Res. 1997 Sep-Oct;17(5A):3665–3669. [PubMed] [Google Scholar]
  4. BLOOM H. J., RICHARDSON W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. doi: 10.1038/bjc.1957.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Balbín M., López-Otín C. Hormonal regulation of the human pepsinogen C gene in breast cancer cells. Identification of a cis-acting element mediating its induction by androgens, glucocorticoids, and progesterone. J Biol Chem. 1996 Jun 21;271(25):15175–15181. doi: 10.1074/jbc.271.25.15175. [DOI] [PubMed] [Google Scholar]
  6. Bharaj B. S., Angelopoulou K., Diamandis E. P. Rapid sequencing of the p53 gene with a new automated DNA sequencer. Clin Chem. 1998 Jul;44(7):1397–1403. [PubMed] [Google Scholar]
  7. Bharaj B. S., Vassilikos E. J., Diamandis E. P. Rapid and accurate determination of (CAG)n repeats in the androgen receptor gene using polymerase chain reaction and automated fragment analysis. Clin Biochem. 1999 Jul;32(5):327–332. doi: 10.1016/s0009-9120(99)00023-5. [DOI] [PubMed] [Google Scholar]
  8. Bharaj B., Scorilas A., Giai M., Diamandis E. P. TA repeat polymorphism of the 5alpha-reductase gene and breast cancer. Cancer Epidemiol Biomarkers Prev. 2000 Apr;9(4):387–393. [PubMed] [Google Scholar]
  9. Bryan R. M., Mercer R. J., Bennett R. C., Rennie G. C., Lie T. H., Morgan F. J. Androgen receptors in breast cancer. Cancer. 1984 Dec 1;54(11):2436–2440. doi: 10.1002/1097-0142(19841201)54:11<2436::aid-cncr2820541121>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  10. Coffey D. S. Prostate cancer. An overview of an increasing dilemma. Cancer. 1993 Feb 1;71(3 Suppl):880–886. doi: 10.1002/1097-0142(19930201)71:3+<880::aid-cncr2820711403>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  11. Dressler L. G., Seamer L. C., Owens M. A., Clark G. M., McGuire W. L. DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer. 1988 Feb 1;61(3):420–427. doi: 10.1002/1097-0142(19880201)61:3<420::aid-cncr2820610303>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  12. Ferguson R. A., Yu H., Kalyvas M., Zammit S., Diamandis E. P. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clin Chem. 1996 May;42(5):675–684. [PubMed] [Google Scholar]
  13. Foekens J. A., van Putten W. L., Portengen H., de Koning H. Y., Thirion B., Alexieva-Figusch J., Klijn J. G. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. J Clin Oncol. 1993 May;11(5):899–908. doi: 10.1200/JCO.1993.11.5.899. [DOI] [PubMed] [Google Scholar]
  14. Gormley G. J., Stoner E., Bruskewitz R. C., Imperato-McGinley J., Walsh P. C., McConnell J. D., Andriole G. L., Geller J., Bracken B. R., Tenover J. S. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992 Oct 22;327(17):1185–1191. doi: 10.1056/NEJM199210223271701. [DOI] [PubMed] [Google Scholar]
  15. Grattarola R. Androgens in breast cancer. I. Atypical endometrial hyperplasia and breast cancer in married premenopausal women. Am J Obstet Gynecol. 1973 Jun 1;116(3):423–428. doi: 10.1016/s0002-9378(15)31304-1. [DOI] [PubMed] [Google Scholar]
  16. Grattarola R., Secreto G., Recchione C., Castellini W. Androgens in breast cancer. II. Endometrial adenocarcinoma and breast cancer in married postmenopausal women. Am J Obstet Gynecol. 1974 Jan 15;118(2):173–178. [PubMed] [Google Scholar]
  17. Griniatsos J., Diamantis E., Gioti J., Karyda I., Vassilopoulos P. P., Agnanti N. Correlation of prostate specific antigen immunoactivity (IR-PSA) to other prognostic factors in female breast cancer. Anticancer Res. 1998 Jan-Feb;18(1B):683–688. [PubMed] [Google Scholar]
  18. Hall R. E., Clements J. A., Birrell S. N., Tilley W. D. Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours. Br J Cancer. 1998 Aug;78(3):360–365. doi: 10.1038/bjc.1998.499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hill P., Garbaczewski L., Wynder E. L. Testosterone in breast fluid. Lancet. 1983 Apr 2;1(8327):761–761. doi: 10.1016/s0140-6736(83)92044-5. [DOI] [PubMed] [Google Scholar]
  20. Hähnel R., Hähnel E. Expression of the PIP/GCDFP-15 gene and survival in breast cancer. Virchows Arch. 1996 Dec;429(6):365–369. doi: 10.1007/BF00198441. [DOI] [PubMed] [Google Scholar]
  21. Kantoff P. W., Febbo P. G., Giovannucci E., Krithivas K., Dahl D. M., Chang G., Hennekens C. H., Brown M., Stampfer M. J. A polymorphism of the 5 alpha-reductase gene and its association with prostate cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 1997 Mar;6(3):189–192. [PubMed] [Google Scholar]
  22. Key T. J., Pike M. C. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol. 1988 Jan;24(1):29–43. doi: 10.1016/0277-5379(88)90173-3. [DOI] [PubMed] [Google Scholar]
  23. Kuenen-Boumeester V., Van der Kwast T. H., Claassen C. C., Look M. P., Liem G. S., Klijn J. G., Henzen-Logmans S. C. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer. 1996 Aug;32A(9):1560–1565. doi: 10.1016/0959-8049(96)00112-8. [DOI] [PubMed] [Google Scholar]
  24. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  25. Labrie F., Sugimoto Y., Luu-The V., Simard J., Lachance Y., Bachvarov D., Leblanc G., Durocher F., Paquet N. Structure of human type II 5 alpha-reductase gene. Endocrinology. 1992 Sep;131(3):1571–1573. doi: 10.1210/endo.131.3.1505484. [DOI] [PubMed] [Google Scholar]
  26. López-Otín C., Diamandis E. P. Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr Rev. 1998 Aug;19(4):365–396. doi: 10.1210/edrv.19.4.0337. [DOI] [PubMed] [Google Scholar]
  27. Magklara A., Scorilas A., Catalona W. J., Diamandis E. P. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin Chem. 1999 Nov;45(11):1960–1966. [PubMed] [Google Scholar]
  28. Magklara A., Scorilas A., Stephan C., Kristiansen G. O., Hauptmann S., Jung K., Diamandis E. P. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology. 2000 Sep 1;56(3):527–532. doi: 10.1016/s0090-4295(00)00621-x. [DOI] [PubMed] [Google Scholar]
  29. Makridakis N. M., di Salle E., Reichardt J. K. Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II. Pharmacogenetics. 2000 Jul;10(5):407–413. doi: 10.1097/00008571-200007000-00004. [DOI] [PubMed] [Google Scholar]
  30. Makridakis N., Ross R. K., Pike M. C., Chang L., Stanczyk F. Z., Kolonel L. N., Shi C. Y., Yu M. C., Henderson B. E., Reichardt J. K. A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res. 1997 Mar 15;57(6):1020–1022. [PubMed] [Google Scholar]
  31. Pisani P., Parkin D. M., Bray F., Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999 Sep 24;83(1):18–29. doi: 10.1002/(sici)1097-0215(19990924)83:1<18::aid-ijc5>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  32. Recchione C., Venturelli E., Manzari A., Cavalleri A., Martinetti A., Secreto G. Testosterone, dihydrotestosterone and oestradiol levels in postmenopausal breast cancer tissues. J Steroid Biochem Mol Biol. 1995 Jun;52(6):541–546. doi: 10.1016/0960-0760(95)00017-t. [DOI] [PubMed] [Google Scholar]
  33. Reichardt J. K., Makridakis N., Henderson B. E., Yu M. C., Pike M. C., Ross R. K. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res. 1995 Sep 15;55(18):3973–3975. [PubMed] [Google Scholar]
  34. Reiner A., Kolb R., Reiner G., Jakesz R., Schemper M., Spona J. Prognostic significance of steroid hormone receptors and histopathological characterization of human breast cancer. J Cancer Res Clin Oncol. 1987;113(3):285–290. doi: 10.1007/BF00396387. [DOI] [PubMed] [Google Scholar]
  35. Ross R. K., Bernstein L., Lobo R. A., Shimizu H., Stanczyk F. Z., Pike M. C., Henderson B. E. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet. 1992 Apr 11;339(8798):887–889. doi: 10.1016/0140-6736(92)90927-u. [DOI] [PubMed] [Google Scholar]
  36. Scorilas A., Diamandis E. P., Levesque M. A., Papanastasiou-Diamandi A., Khosravi M. J., Giai M., Ponzone R., Roagna R., Sismondi P., López-Otin C. Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: an independent favorable prognostic factor in node-positive patients. Clin Cancer Res. 1999 Jul;5(7):1778–1785. [PubMed] [Google Scholar]
  37. Scorilas A., Talieri M., Ardavanis A., Courtis N., Dimitriadis E., Yotis J., Tsiapalis C. M., Trangas T. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer. Cancer Res. 2000 Oct 1;60(19):5427–5433. [PubMed] [Google Scholar]
  38. Scorilas A., Trangas T., Yotis J., Pateras C., Talieri M. Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis. Br J Cancer. 1999 Dec;81(8):1385–1391. doi: 10.1038/sj.bjc.6693404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Scorilas A., Yu H., Soosaipillai A. R., Gregorakis A. K., Diamandis E. P. Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy. Clin Chim Acta. 2000 Feb 25;292(1-2):127–138. doi: 10.1016/s0009-8981(99)00211-9. [DOI] [PubMed] [Google Scholar]
  40. Secreto G., Fariselli G., Bandieramonte G., Recchione C., Dati V., Di Pietro S. Androgen excretion in women with a family history of breast cancer or with epithelial hyperplasia or cancer of the breast. Eur J Cancer Clin Oncol. 1983 Jan;19(1):5–10. doi: 10.1016/0277-5379(83)90389-9. [DOI] [PubMed] [Google Scholar]
  41. Secreto G., Venturelli E., Bucci A., Piromalli D., Fariselli G., Galante E. Intratumour amount of sex steroids in elderly breast cancer patients. An approach to the biological characterization of mammary tumours in the elderly. J Steroid Biochem Mol Biol. 1996 Aug;58(5-6):557–561. doi: 10.1016/0960-0760(96)00076-3. [DOI] [PubMed] [Google Scholar]
  42. Secreto G., Zumoff B. Paradoxical effects associated with supranormal urinary testosterone excretion in premenopausal women with breast cancer: increased risk of postmastectomy recurrence and higher remission rate after ovariectomy. Cancer Res. 1983 Jul;43(7):3408–3411. [PubMed] [Google Scholar]
  43. Stoll B. A., Secreto G. New hormone-related markers of high risk to breast cancer. Ann Oncol. 1992 Jun;3(6):435–438. doi: 10.1093/oxfordjournals.annonc.a058230. [DOI] [PubMed] [Google Scholar]
  44. Søreide J. A., Lea O. A., Varhaug J. E., Skarstein A., Kvinnsland S. Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol. 1992 Apr;18(2):112–118. [PubMed] [Google Scholar]
  45. Vermeulen A., Deslypere J. P., Paridaens R., Leclercq G., Roy F., Heuson J. C. Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol. 1986 Apr;22(4):515–525. doi: 10.1016/0277-5379(86)90121-5. [DOI] [PubMed] [Google Scholar]
  46. Vilchis F., Hernández D., Canto P., Méndez J. P., Chávez B. Codon 89 polymorphism of the human 5alpha-steroid reductase type 2 gene. Clin Genet. 1997 Jun;51(6):399–402. doi: 10.1111/j.1399-0004.1997.tb02498.x. [DOI] [PubMed] [Google Scholar]
  47. Vizoso F., Sánchez L. M., Díez-Itza I., Merino A. M., López-Otín C. Pepsinogen C is a new prognostic marker in primary breast cancer. J Clin Oncol. 1995 Jan;13(1):54–61. doi: 10.1200/JCO.1995.13.1.54. [DOI] [PubMed] [Google Scholar]
  48. Wigley W. C., Prihoda J. S., Mowszowicz I., Mendonca B. B., New M. I., Wilson J. D., Russell D. W. Natural mutagenesis study of the human steroid 5 alpha-reductase 2 isozyme. Biochemistry. 1994 Feb 8;33(5):1265–1270. doi: 10.1021/bi00171a029. [DOI] [PubMed] [Google Scholar]
  49. Wilson J. D., Griffin J. E., Russell D. W. Steroid 5 alpha-reductase 2 deficiency. Endocr Rev. 1993 Oct;14(5):577–593. doi: 10.1210/edrv-14-5-577. [DOI] [PubMed] [Google Scholar]
  50. Yu H., Diamandis E. P., Levesque M., Giai M., Roagna R., Ponzone R., Sismondi P., Monne M., Croce C. M. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat. 1996;40(2):171–178. doi: 10.1007/BF01806212. [DOI] [PubMed] [Google Scholar]
  51. Yu H., Giai M., Diamandis E. P., Katsaros D., Sutherland D. J., Levesque M. A., Roagna R., Ponzone R., Sismondi P. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res. 1995 May 15;55(10):2104–2110. [PubMed] [Google Scholar]
  52. Yu H., Levesque M. A., Clark G. M., Diamandis E. P. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin Cancer Res. 1998 Jun;4(6):1489–1497. [PubMed] [Google Scholar]
  53. Zarghami N., Grass L., Diamandis E. P. Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer. 1997;75(4):579–588. doi: 10.1038/bjc.1997.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Zubiaga A. M., Belasco J. G., Greenberg M. E. The nonamer UUAUUUAUU is the key AU-rich sequence motif that mediates mRNA degradation. Mol Cell Biol. 1995 Apr;15(4):2219–2230. doi: 10.1128/mcb.15.4.2219. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES